BACKGROUND: Increasing evidence supports the association between @entity5052 and @entity740 ( @entity740 ); however, there are conflicting data regarding the role of @entity5052 in the progression of @entity740 . This study retrospectively assessed the longitudinal association between @entity414 (UA) level and @entity740 progression in a Chinese population lived in Taiwan. METHODS: @entity1 with physician diagnosis of @entity5052 or receiving urate-lowering therapy between 2003 and 2005 were identified in the electronic medical records (EMR) of a tertiary medical center and were followed up until December 31, 2011. @entity1 were divided into four UA categories at the cut-off 6, 8, and 10 mg/dL. @entity740 progression was estimated by the change of estimated glomerular filtration rate (eGFR) in the linear mixed models. @entity177 was defined as an eGFR less than 15 mL/min/1.73 m2 or requiring renal replacement therapy. RESULTS: A total of 739 @entity1 were analyzed. In the full-adjusted model, @entity1 with a baseline UA level >= 6 mg/dL had greater decline in eGFR ((b = -9.6, 95% CI -16.1, -3.1), comparing to those with a UA level less than 6 mg/dL. When stratifying @entity1 into four UA categories, all three @entity5052 categories (UA6-8, 8-10, >= 10 mg/dL) associated with a greater decline in eGFR over the follow-up period with an increasing dose-response, comparing to the lowest UA category. The risk of progression to @entity177 increased 7% (hazard ratio 1.07, 95% CI 1.00, 1.14) for each 1mg/dL increase in baseline UA level. The influences of @entity5052 on eGFR decline and the risk of @entity177 were more prominent in @entity1 without @entity644 than those with @entity644 . CONCLUSION: Our study showed a higher @entity414 level is associated with a significant rapid decline in eGFR and a higher risk of @entity177 , particularly in @entity1 without @entity644 . Our findings suggest @entity5052 is a potential modifiable factor of @entity740 progression.

Serum XXXX and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'incident chronic kidney disease'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure', 'Kidney failure', 'kidney failure'] @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia'] @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']
@entity414 :: (MESH:D014527,Chemical) :: ['Uric Acid']
